Ultrasonographic prediction of highly aggressive telomerase reverse transcriptase (TERT) promoter-mutated papillary thyroid cancer

被引:14
|
作者
Kim, Tae Hyuk [1 ]
Ki, Chang-Seok [2 ]
Hahn, Soo Yeon [3 ]
Oh, Young Lyun [4 ]
Jang, Hye Won [5 ]
Kim, Sun Wook [1 ]
Chung, Jae Hoon [1 ]
Shin, Jung Hee [3 ]
机构
[1] Sungkyunkwan Univ, Div Endocrinol & Metab, Dept Med, Thyroid Ctr,Sch Med,Samsung Med Ctr, Seoul, South Korea
[2] Sungkyunkwan Univ, Dept Lab Med & Genet, Samsung Med Ctr, Sch Med, Seoul, South Korea
[3] Sungkyunkwan Univ, Dept Radiol, Samsung Med Ctr, Sch Med, Seoul, South Korea
[4] Sungkyunkwan Univ, Dept Pathol, Samsung Med Ctr, Sch Med, Seoul, South Korea
[5] Sungkyunkwan Univ, Dept Med Educ, Sch Med, Seoul, South Korea
关键词
TERT promoter; Thyroid cancer; Papillary cancer; Ultrasonography; Prediction; BRAF(V600E) MUTATION; NODULES; ASSOCIATION; CARCINOMA; MANAGEMENT; DIAGNOSIS; MELANOMA; BREAST;
D O I
10.1007/s12020-017-1340-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose Telomerase reverse transcriptase promoter mutations are found in highly aggressive thyroid malignancies. Our aim was to define the ultrasonographic features of telomerase reverse transcriptase promoter-mutated papillary thyroid cancer and to evaluate their predictive performances. Methods Ultrasonographic findings were reviewed for 185 patients with surgically confirmed papillary thyroid cancer between 1994 and 2004. Genomic DNA to identify telomerase reverse transcriptase promoter mutations was extracted from archived surgical specimens. Logistic regression analysis was performed to compare clinical factors and ultrasonographic findings between telomerase reverse transcriptase promoter-mutated and wild-type papillary thyroid cancers. Results A telomerase reverse transcriptase promoter mutation was detected in 8.1% (15 of 185) of specimens from papillary thyroid cancer patients with a strong trend toward increasing age. Nonparallel orientation and microlobulated margin were independent ultrasonographic findings for predicting telomerase reverse transcriptase promoter-mutated papillary thyroid cancer in patients over 50 years (odds ratio 5.898, 95% confidence interval 1.092-31.851, P = 0.039 for orientation; odds ratio 5.813, 95% confidence interval 1.320-25.602, P = 0.020 for margin). Prevalence of telomerase reverse transcriptase promoter mutations increased to 50.0% in papillary thyroid cancer patients older than 50 years with both ultrasonographic findings and was 0% in patients without either finding. For identifying telomerase reverse transcriptase promoter-mutated papillary thyroid cancer, ultrasonographic had 64.3% sensitivity, 80.8% specificity, 50.0% positive predictive value and 88.4% negative predictive value. Conclusions Telomerase reverse transcriptase promoter-mutated papillary thyroid cancer could be suggested by the ultrasonographic features of nonparallel orientation and microlobulated margin in patients older than 50 years. Prebiopsy recognition of this unique ultrasonographic pattern would mandate the nodule fall into a "biopsy suggested" category.
引用
收藏
页码:234 / 240
页数:7
相关论文
共 50 条
  • [41] Telomere Length and Telomerase Reverse Transcriptase Gene Copy Number in Patients with Papillary Thyroid Carcinoma
    Jendrzejewski, Jaroslaw
    Tomsic, Jerneja
    Lozanski, Gerard
    Labanowska, Jadwiga
    He, Huiling
    Liyanarachchi, Sandya
    Nagy, Rebecca
    Ringel, Matthew D.
    Kloos, Richard T.
    Heerema, Nyla A.
    de la Chapelle, Albert
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2011, 96 (11): : E1876 - E1880
  • [42] Telomerase reverse transcriptase mutations are independent predictor of disease-free survival in Middle Eastern papillary thyroid cancer
    Bu, Rong
    Siraj, Abdul K.
    Divya, Sasidharan Padmaja
    Kong, Yan
    Parvathareddy, Sandeep Kumar
    Al-Rasheed, Maha
    Al-Obaisi, Khadija A. S.
    Victoria, Ingrid G.
    Al-Sobhi, Saif S.
    Al-Dawish, Mohammed
    Al-Dayel, Fouad
    Al-Kuraya, Khawla S.
    INTERNATIONAL JOURNAL OF CANCER, 2018, 142 (10) : 2028 - 2039
  • [43] Promoter region mutations of the telomerase reverse transcriptase (TERT) gene in head and neck squamous cell carcinoma
    Yilmaz, Ismail
    Erkul, Bulent Evren
    Sari, Sule Ozturk
    Issin, Gizem
    Tural, Ersin
    Terzi, Neslihan Kaya Terzi
    Karatay, Huseyin
    Celik, Mehmet
    Ulusan, Murat
    Bilgic, Bilge
    ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY, 2020, 130 (01): : 63 - 70
  • [44] Differential Regulation of Human and Mouse Telomerase Reverse Transcriptase (TERT) Promoter Activity During Testis Development
    Weise, J. M.
    Guenes, C.
    MOLECULAR REPRODUCTION AND DEVELOPMENT, 2009, 76 (03) : 309 - 317
  • [45] Characterization of human telomerase reverse transcriptase promoter methylation and transcription factor binding in differentiated thyroid cancer cell lines
    Avin, Brittany A.
    Wang, Yongchun
    Gilpatrick, Timothy
    Workman, Rachael E.
    Lee, Isac
    Timp, Winston
    Umbricht, Christopher B.
    Zeiger, Martha A.
    GENES CHROMOSOMES & CANCER, 2019, 58 (08): : 530 - 540
  • [46] Exploring the epigenetic regulation of telomerase reverse transcriptase (TERT) in human cancer cell lines
    McKelvey, Brittany A.
    Zeiger, Martha A.
    Umbricht, Christopher B.
    MOLECULAR ONCOLOGY, 2020, 14 (10) : 2355 - 2357
  • [47] Correlation between telomerase reverse transcriptase messenger RNA expression and survival of patients with papillary thyroid carcinoma
    Kwon, Jae Hyun
    Yi, Jin Wook
    SURGERY, 2021, 169 (01) : 43 - 49
  • [48] Telomerase reverse transcriptase (TERT) promoter mutation is a rare event in ovarian clear cell carcinomas in the Japanese population
    Katagiri, H.
    Nakayama, K.
    Nakamura, K.
    Razia, S.
    Sato, E.
    Ishibashi, T.
    Ishikawa, M.
    Minamoto, T.
    Iida, K.
    Otsuki, Y.
    Nakayama, S.
    Ishikawa, N.
    Kyo, S.
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2019, 40 (02) : 220 - 223
  • [49] Tumor-specific gene therapy for undifferentiated thyroid carcinoma utilizing the telomerase reverse transcriptase promoter
    Takeda, T
    Inaba, H
    Yamazaki, M
    Kyo, S
    Miyamoto, T
    Suzuki, S
    Ehara, T
    Kakizawa, T
    Hara, M
    DeGroot, LJ
    Hashizume, K
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (08): : 3531 - 3538
  • [50] Telomerase reverse transcriptase promoter mutations in thyroid carcinomas: implications in precision oncology-a narrative review
    Yuan, Xiaotian
    Liu, Tiantian
    Xu, Dawei
    ANNALS OF TRANSLATIONAL MEDICINE, 2020, 8 (19)